UCP2 and triple-A syndrome: The incident rate of AAA in UCP-2-/-ApoE-/- mice after Ang-II treatment was 83.9% (26 of 31), higher than the rate in the UCP-2+/+ApoE-/- mice (55%, 11 of 20).